Trial Details
COMPLETEDBasic Information
| Clinical ID | c1270 |
|---|---|
| Identifier | NCT05291689 |
| Trial Title | A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Inflammatory Bowel Diseases|Colitis, Ulcerative |
| Interventions | DRUG: MORF-057 |
Participant Information
| Sponsor | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) |
|---|---|
| City | Tampa |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2022-04-13 |
|---|---|
| Primary Completion Date | 2023-10-18 |
| Completion Date | 2025-02-19 |